{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=13", "query": { "condition": "Metastatic Skin Cancer", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 2838, "total_pages": 284, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:30:30.983Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05588453", "title": "Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Pathologic Stage IV Cutaneous Melanoma AJCC v8" ], "interventions": [ { "name": "Natural Killer Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Kari Kendra", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2023-03-01", "completion_date": "2027-04-15", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-11-15T12:30:30.983Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05588453" }, { "nct_id": "NCT02302339", "title": "A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "glembatumumab vedotin", "type": "DRUG" }, { "name": "glembatumumab vedotin and varlilumab", "type": "DRUG" }, { "name": "glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)", "type": "DRUG" }, { "name": "glembatumumab vedotin and CDX-301", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2014-11", "completion_date": "2018-10-03", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-11-15T12:30:30.983Z", "location_count": 14, "location_summary": "Los Angeles, California • San Francisco, California • Fort Myers, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02302339" }, { "nct_id": "NCT01001299", "title": "A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Melanoma" ], "interventions": [ { "name": "Drug cocktail", "type": "DRUG" }, { "name": "RO5185426", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2009-11-30", "completion_date": "2012-02-29", "has_results": true, "last_update_posted_date": "2017-08-15", "last_synced_at": "2026-11-15T12:30:30.983Z", "location_count": 5, "location_summary": "Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01001299" }, { "nct_id": "NCT00003750", "title": "Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma (Skin)", "Neuroblastoma", "Sarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "hu14.18-IL2 fusion protein", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 28, "start_date": "2001-10", "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2014-08-08", "last_synced_at": "2026-11-15T12:30:30.983Z", "location_count": 54, "location_summary": "Little Rock, Arkansas • Duarte, California • La Jolla, California + 44 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003750" }, { "nct_id": "NCT00324324", "title": "Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Infection", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Ovarian Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "moxifloxacin hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 240, "start_date": "2006-05", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-11-15T12:30:30.983Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324324" }, { "nct_id": "NCT04191499", "title": "A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Inavolisib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2020-01-29", "completion_date": "2027-11-15", "has_results": true, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-11-15T12:30:30.983Z", "location_count": 10, "location_summary": "Beverly Hills, California • Boston, Massachusetts • New York, New York + 7 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Chattanooga", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04191499" }, { "nct_id": "NCT00338377", "title": "Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Dendritic Cell Immunization", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "T-Cells", "type": "BIOLOGICAL" }, { "name": "Interleukin-2", "type": "BIOLOGICAL" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Intrathecal T-Cells", "type": "BIOLOGICAL" }, { "name": "Intrathecal Interleukin-2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1230, "start_date": "2006-02-01", "completion_date": "2030-02-28", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-11-15T12:30:30.983Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00338377" }, { "nct_id": "NCT05382299", "title": "Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple Negative Breast Cancer", "PD-L1 Negative" ], "interventions": [ { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 623, "start_date": "2022-07-20", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-11-15T12:30:30.983Z", "location_count": 130, "location_summary": "Tucson, Arizona • Burbank, California • La Jolla, California + 92 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05382299" }, { "nct_id": "NCT01186601", "title": "Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "PET tracer (BAY94-9392)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lantheus Biosciences Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 30, "start_date": "2010-12", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2014-11-13", "last_synced_at": "2026-11-15T12:30:30.983Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186601" }, { "nct_id": "NCT00006007", "title": "LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 59, "start_date": "2000-12", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2016-12-07", "last_synced_at": "2026-11-15T12:30:30.983Z", "location_count": 23, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006007" } ] }